Group items tagged

Addition of milk prevents vascular protective effects of tea. Lorenz M, Jochmann N, von Krosigk A, Martus P, Baumann G, Stangl K, Stangl V. Eur Heart J. 2007 Jan;28(2):219-23. Epub 2007 Jan 9. PMID: 17213230 doi:10.1093/eurheartj/ehl442 In conclusion, milk may counteract the favourable health effects of tea on vascular function. The finding that the tea-induced improvement of vascular function in humans is completely attenuated after addition of milk may have broad implications on the mode of tea preparation and consumption. In addition, it indicates that caution is warranted in the design of studies involving nutritional flavonoids.

15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. J Exp Med. 2004 Jul 5;200(1):69-78. PMID: 15238606

Arginine and cancer. Lind DS. J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S. Review. PMID: 15465796

The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Kawashima S. Endothelium. 2004 Mar-Apr;11(2):99-107. Review. PMID: 15370069 DOI: 10.1080/10623320490482637

Hypertension, endothelial dysfunction and cardiovascular risk] Nitenberg A. Arch Mal Coeur Vaiss. 2006 Oct;99(10):915-21. Review. French. PMID: 17100143

"Quality of HDL differs in diabetics but improves with niacin therapy December 22, 2009 | Michael O'Riordan Hannover, Germany - A small study published this week hints that the effects of HDL cholesterol differ in healthy patients from those with diabetes mellitus [1]. HDL cholesterol in individuals with diabetes has impaired endothelial protective functions compared with the HDL from healthy subjects, although treatment with extended-release niacin can improve these endothelial protective effects, according to researchers. Publishing their findings online December 21, 2009 in Circulation, lead investigator Dr Sajoscha Sorrentino (Hannover Medical School, Germany) and colleagues write that because recent HDL-raising intervention studies have yielded mixed results, "circulating HDL-cholesterol levels alone likely do not represent an adequate measure of therapeutic efficacy, and indexes of HDL functionality are urgently needed for assessment of the potential of HDL-targeted therapies to exert vasoprotective effects." Speaking with heartwire, senior investigator Dr Ulf Landmesser (University of Zürich, Switzerland), said the results have implications for clinical research. "We have to understand that we can't look only at the HDL levels in the plasma, but we need to look at the quality," he said. "The quality of the HDL is not the same in different patients. This is very important for targeting HDL as a treatment. Second, niacin therapy is a promising way not only to raise HDL but also to improve the quality; it is a good treatment option, especially if the larger outcomes data are positive.""

Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U. Circulation. 2009 Dec 21. [Epub ahead of print] PMID: 20026785 doi: 10.1161/CIRCULATIONAHA.108.836346 Conclusions-HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects. ER niacin therapy not only increases HDL plasma levels but markedly improves endothelial-protective functions of HDL in these patients, which is potentially more important.